Patent application number | Description | Published |
20080212866 | Quantitative, multispectral image analysis of tissue specimens stained with quantum dots - A biological sample such as a tissue section is stained with one or more quantum dots and possibly other fluorophores (total number of fluorophores N). A camera coupled to a microscope generates an image of the specimen at a plurality of different wavelengths within the emission spectral band of the N fluorophores. An analysis module calculates coefficients C | 09-04-2008 |
20100196902 | PROSTATE CANCER BIOMARKERS - Disclosed are biomarkers, at least, useful for the diagnosis and/or prognosis of cancer and for making treatment decisions in cancer, for example prostate cancer. | 08-05-2010 |
20100209928 | Grading, Staging and prognosing Cancer using Osteopontin-C - The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3). | 08-19-2010 |
20110235879 | Quantitative, multispectral image analysis of tissue specimens stained with quantum dots - A biological sample such as a tissue section is stained with one or more quantum dots and possibly other fluorophores (total number of fluorophores N). A camera coupled to a microscope generates an image of the specimen at a plurality of different wavelengths within the emission spectral band of the N fluorophores. An analysis module calculates coefficients C | 09-29-2011 |
20110235880 | Quantitative, multispectral image analysis of tissue specimens stained with quantum dots - A biological sample such as a tissue section is stained with one or more quantum dots and possibly other fluorophores (total number of fluorophores N). A camera coupled to a microscope generates an image of the specimen at a plurality of different wavelengths within the emission spectral band of the N fluorophores. An analysis module calculates coefficients C | 09-29-2011 |
20110235881 | Quantitative, multispectral image analysis of tissue specimens stained with quantum dots - A biological sample such as a tissue section is stained with one or more quantum dots and possibly other fluorophores (total number of fluorophores N). A camera coupled to a microscope generates an image of the specimen at a plurality of different wavelengths within the emission spectral band of the N fluorophores. An analysis module calculates coefficients C | 09-29-2011 |
20110238325 | Quantitative, multispectral image analysis of tissue specimens stained with quantum dots - A biological sample such as a tissue section is stained with one or more quantum dots and possibly other fluorophores (total number of fluorophores N). A camera coupled to a microscope generates an image of the specimen at a plurality of different wavelengths within the emission spectral band of the N fluorophores. An analysis module calculates coefficients C | 09-29-2011 |
20120200694 | MULTI-MODALITY CONTRAST AND BRIGHTFIELD CONTEXT RENDERING FOR ENHANCED PATHOLOGY DETERMINATION AND MULTI-ANALYTE DETECTION IN TISSUE - Multiple modality contrast can be used to produce images that can be combined and rendered to produce images similar to those produced with wavelength absorbing stains viewed under transmitted white light illumination. Images obtained with other complementary contrast modalities can be presented using engineered color schemes based on classical contrast methods used to reveal the same anatomical structures and histochemistry, thereby providing relevance to medical training and experience. Dark-field contrast images derived from refractive index and fluorescent DAPI counterstain images are combined to produce images similar to those obtained with conventional H&E staining for pathology interpretation. Such multi-modal image data can be streamed for live navigation of histological samples, and can be combined with molecular localizations of genetic DNA probes (FISH), sites of mRNA expression (mRNA-ISH), and immunohistochemical (IHC) probes localized on the same tissue sections, used to evaluate and map tissue sections prepared for imaging mass spectrometry. | 08-09-2012 |
20120220672 | Presence of ERG Gene Rearrangements and Protein Over-expression in Low Grade PIN (LG-PIN) in Prostate Biopsies - The present disclosure relates to methods for the early detection of ERG over-expression, gene rearrangements, and diagnosis and/or prognosis of prostate cancer using a combined ERG IHC-FISH assay. | 08-30-2012 |
20120224044 | Quantitative, Multispectral Image Analysis of Tissue Specimens Stained with Quantum Dots - A biological sample such as a tissue section is stained with one or more quantum dots and possibly other fluorophores (total number of fluorophores N). A camera coupled to a microscope generates an image of the specimen at a plurality of different wavelengths within the emission spectral band of the N fluorophores. An analysis module calculates coefficients C1 . . . CN at each pixel which are related to the concentration of each of the individual fluorophores. Morphological processing instructions find biological structures. A display module displays quantitative analysis results to the user. The quantitative analysis display includes histograms of the biological structures, scatter plots of fluorophore concentrations, statistical data, spectral data, image data and still others. | 09-06-2012 |
Patent application number | Description | Published |
20100150925 | TREATMENT OF B-CELL CANCERS WITH ANTI-CD70 ANTIBODY-DRUG CONJUGATES - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of a CD70-expressing cancer, comprising administering to a subject the disclosed pharmaceutical compositions. | 06-17-2010 |
20100158910 | TREATMENT OF RENAL CELL CARCINOMA WITH ANTI-CD70 ANTIBODY-DRUG CONJUGATES - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing a cancer, comprising administering to a subject the disclosed pharmaceutical compositions. | 06-24-2010 |
20100183636 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions. | 07-22-2010 |
20120251559 | Treatment of B-Cell Cancers With Anti-CD70 Antibody-Drug Conjugates - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of a CD70-expressing cancer, comprising administering to a subject the disclosed pharmaceutical compositions. | 10-04-2012 |
20120288512 | Anti-CD70 Antibody-Drug Conjugates and Their Use for the Treatment of Cancer and Immune Disorders - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions. | 11-15-2012 |